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Objective: Retrospective analysis of feasibility, safety and advantages of device closure of
patent ductus arteriosus (PDA) using only venous access.
Background: Arterial access for transcatheter device closure of PDA has been a standard
practice, but has inherent complications, especially in infants.
Method: Records of patients who underwent PDA device closure from 2004 to 2012 were
reviewed. Echocardiography was used for patient selection and for assessment of proce-
dural outcome.
Result: 151 out of 179 patients underwent PDA device closure with venous access alone,
weighing 2.2e58 kg with half <10 kg and follow up of 6 monthse8 years. Fluoroscopic time
ranged from 2.2 to 16 min. Immediate closure was achieved in 146 patients. Two patients
had new-onset left pulmonary artery turbulence and one had residual flow.
Conclusion: PDA device closure without arterial access can be accomplished safely and
effectively in vast majority of patients including infants.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction in 1970, the incidence of femoral artery thrombosis hasPatentductusarteriosus (PDA) that ismoderateor large requires
attention in infancy because of symptoms of heart failure,
frequent respiratory infections and failure to thrive.1,2 Arterial
access is often obtained during PDAdevice closure to profile the
duct and to assess the outcome of device deployment. This re-
quires heparinization, as it carries a small risk of femoral arte-
rial occlusion.Since the introductionofsystemicheparinization; fax: þ91 40 23608050.
m (G. Garg).
2013, Cardiological Sociedecreasedbut incidenceof femoral artery relatedcomplications
cannot be ignored, especially in children less than 10 kg
weight.3,4 Apart fromthrombosis, otherpotential issues include
bleeding, longer catheterization and fluoroscopic time and
probably prolonged hospital stay.We present a comprehensive
reviewof transcatheterPDAdeviceclosure in179patientsovera
period of eight years, out of which 151 (84%) underwent suc-
cessful closure of PDA without femoral arterial access.ty of India. All rights reserved.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 5 4 6e5 5 1 5472. Methods
2.1. Study design
From August 2004 onwards, we have been attempting to close
PDA using venous access alone. The records of all patients
who underwent transcatheter closure of PDA between 1st
August 2004 and 31st May 2012 at our institution were
reviewed. Patients in whom the intention was to close the
duct without arterial access were the focus of this study.Fig. 1 e Hand injection through long sheath in lateral
projection delineating PDA via retrograde filling; a conical
shaped structure with wide end towards aorta and
tapering end (white arrow) towards pulmonary artery.
MPA e main pulmonary artery.2.2. Patient selection
Device closure was attempted in patients with hemodynam-
ically significant PDA. A detailed echocardiographic evalua-
tion of the duct morphology was performed for all patients
undergoing PDA closure as part of an institutional protocol.
This was performed using broadband 1e3 MHz, 3e8 MHz and
5e12 MHz frequency transducers (Sonos 7500, Philips). The
duct diameter was measured in a high parasternal long axis
view at the point where it opened into the pulmonary artery.
Since this measurement varies with different phases of car-
diac cycle, the maximum measured diameter at pulmonary
artery insertion was reported. Repeated measurements were
made and the most concordant measurement was taken. The
ductal ampulla was defined in the high parasternal long axis
or in the suprasternal long axis view. The ductal ampulla was
considered adequate if its maximal dimension along the long
axis was greater than twice the measured ductal diameter.
Careful two-dimensional and Doppler imaging of the pulmo-
nary artery branch origins was also routinely performed. After
the echocardiogram, the device closure was planned. The
device size was selected as 2 mm more than the measured
duct size.
Device closure using a venous access alone was planned
for all patients except the following situations when arterial
access was considered necessary and was obtained on an
elective basis:
e Patients in whom echocardiographic definition was
considered inadequate.
e Patients with large ducts with severe pulmonary artery
hypertension which needed a diagnostic study to assess
pulmonary vascular resistance (PVR) for reversibility prior
to attempted device closure.
e Small infants with large ducts requiring bigger devices
which can potentially cause descending aortic obstruc-
tion. In this subset of patients, the strategywhichwe used
was to measure the transverse descending aortic diam-
eter just below the duct and if this was less than or equal
to the aortic retention disc (device preselected by duct size
on echocardiographic assessment), the arterial access
was obtained.
e Patients with additional lesions requiring intervention.
Informed consent was obtained. All procedures were per-
formed under conscious sedation with intravenous ketamine
and midazolam and local anesthesia. None of the patients
received general anesthesia. The blood pressure wasmonitored noninvasively. Heparin was not administered at
the start of the procedure.
2.3. Angiographic definition
A 5 French multipurpose catheter was used to cross the duct
from the main pulmonary artery with the help of the straight
end of a 0.025 or 0.035 inch guidewire (Terumo Medical Cor-
poration, Somerset, NJ). The catheter was exchanged with an
appropriate sized long sheath (Cook Medical Inc., Bloo-
mington, IN) (according to the preselected device size on
echocardiography) over an exchange length extra-stiff
guidewire. The duct was profiled in lateral (Fig. 1) and if
required, in right anterior oblique view (Fig. 2) by hand injec-
tion with the tip of the long sheath positioned within the
ductal ampulla or the proximal descending aorta with the stiff
wire still across the sheath. The retrograde blood flow into the
pulmonary artery from the ductal ampulla and proximal
descending thoracic aorta allowed definition of the pulmo-
nary artery insertion of the duct. The ductal size was
measured and was compared with our echocardiographic
measurements.
2.4. Device selection
Device size was selected based on echocardiographic mea-
surements if both echocardiographic and angiographic values
were concordant, otherwise the bigger measurement was
taken. The devices used for ductal closure were Amplatzer
Duct Occluders (AGA Medical Corporation, Golden Valley,
MN), Cardi-O-Fix Duct Occluders (Starway Medical Corpora-
tion) and Lifetech Duct Occluders (ShenZhen Lifetech Scien-
tific Inc.). The devices were selected according to their
availability and cost considerations.
2.5. Device deployment technique
After angiography, the long sheath was repositioned in the
descending aorta and the device was deployed according to
Fig. 2 e Hand injection through long sheath in right
anterior oblique view showing anatomy of PDA with
narrow end (white arrow) towards pulmonary artery.
MPA e main pulmonary artery.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 4 6e5 5 1548the standard technique using tracheal air shadow as the
landmark for duct ampulla and opening of the duct into the
pulmonary artery. The PA pressure was measured after
deployment of the device through the side arm of the long
sheath. The origins of the branch pulmonary arteries were
assessed by hand injections through the long sheath in
anteroposterior and in left anterior oblique view with slight
cranial angulation (Fig. 3). In selected patients, this was
repeated even after release of the device, especially in smaller
children.
The special techniques we have used were:
 To use the Amplatzer perimembranous ventricular septal
defect occluder delivery cable (AGA Medical Corporation,Fig. 3 e Hand injection through long sheath in left anterior
oblique view with cranial angulation after placement of
device (delivery cable still attached) showing normal filling
of branch pulmonary arteries. MPA e main pulmonary
artery; LPA e left pulmonary artery; RPA e right pulmonary
artery.Golden Valley, MN) for deployment of devices in small
children. We found this to be secure and easy to track the
device through the curved portion of the long sheath. The
cable was compatible with Amplatzer and Lifetech duct
occluders.
 In case of kinking of the sheath, we position the sheath deep
in the descending aorta and then track the device to the tip
of the sheath before deploying it in the appropriate position.
Before releasing the device, echocardiography was per-
formed in the cardiac catheterization laboratory. The device
placement was assessed on 2D echocardiography in high
parasternal view and suprasternal view. The correct place-
ment of the device was accepted when the retention skirt was
seen opposite the ampulla in the descending aorta and the
conical portion of the devicewas seen in the pulmonary artery
with a waist at the mouth of the duct (Fig. 4). Color flow
mapping was done to check for residual flow through the duct
as well as turbulence at the origin of the left pulmonary artery
and in the descending aorta (Fig. 5). Small residual color flow
was accepted. Doppler gradients of upto 5 mmHg in the left
pulmonary artery and upto 10 mmHg in the descending aorta
were accepted. The device was deployed and the echocar-
diographic assessments were repeated.
All patients underwent repeat echocardiography before
discharge, where all the above mentioned parameters were
reassessed.
2.6. Discharge and follow up
Patients were discharged 24 h after the procedure if it was
acceptable to the parents. All patients were asked to return for
a follow-up echocardiogram 1 month after the procedure for
assessment of residual flow across the duct and to check for
turbulence at the origin of the left pulmonary artery and
descending aorta. They were then assessed at regular interval
of six months till 3 years after the procedure. Complete eval-
uation including echocardiography was done at each visit.3. Results
From August 2004 to May 2012, we attempted PDA device
closure in 179 patients. Device closure using venous access
alone was achieved in 151 patients [age: 2 months e 34 years
(median 2.7 years) with 50 patients <1 year of age; weight:
2.2e58 kg (median 12.4 kg), including 85 patients with
weight < 10 kg]. The PDA sizes ranged from 1.8 mm to 14 mm
(mean: 4.5  2.3 mm).
Arterial access was required in 28 patients and the reasons
were as follows:
1. Elective arterial access (19 patients), for reasons explained
before
2. Accidental arterial puncture while trying to obtain venous
access (4 patients)
3. Unsatisfactory echocardiographic images for assessment of
results after deployment of the device (3 patients)
4. Unable to obtain venous access (1 patient)
5. Unable to cross into PDA from PA (1 patient).
Fig. 4 e Echocardiographic assessment of device placement
in high parasternal view. The retention skirt seen
occupying the ampullary space and the conical part
projects into pulmonary artery across the duct. RPA e right
pulmonary artery.
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the catheterization laboratory in 146 of the 151 patients. The
residual flow in 4 patients disappeared 24 h after the proce-
dure. Turbulence at the LPA origin was demonstrable in 8
patients out of 151. Three of themhadmild LPA origin stenosis
demonstrated prior to PDA closure which remained sameFig. 5 e Colour Doppler interrogation in (a) parasternal short ax
parasternal short axis view showing normal LPA flow (c) supra
descending aorta. LPA e left pulmonary artery; RPA e right pulafter the procedure. Five patients had new-onset LPA turbu-
lence (peak gradient range 3e15 mmHg). In two patients, the
gradients appeared after device release (there was no turbu-
lence while the cable was attached). Flow at the LPA origin
remained laminar in the remaining patients. Two patients
had new-onset turbulence in the descending aorta with peak
gradients of 8 mmHg and 10 mmHg.
The mean fluoroscopic time for the procedure was
3.5  4.3 min (range: 2.2e16 min). No other complications or
procedural events were recorded. Of patients who required
arterial access, two patients needed overnight heparin for
impairment of lower limb perfusion. So, the need for hep-
arinization for vascular compromise for the whole group was
low (2/179) e 1.1%.
Out of 151 patients, one-month follow up data was avail-
able for 147 patients. Residual PDA flow was seen in one pa-
tient. The gradient in LPA remained unchanged in the 5
patients including 3 patientswho had LPA stenosis prior to the
procedure. The aorta gradients disappeared on follow-up at
one year in both patients.4. Discussion
The first transcatheter closure of PDA was reported by Porst-
mann et al in 1971.5 Closure of PDA is now a well established
and effective procedure for which various devices have been
used.6e10 Interventional closure of PDA is considered as safe
method of duct occlusion but some complications such as
hemolysis, device embolization, infection, and significant
narrowing of the left pulmonary artery or the descending
aorta have been reported in the past.6,11,12 Device emboliza-
tion has been identified as one of the most significant com-
plications of interventional PDA occlusion.13,14 The reported
embolization rate varies, between 0% and 16%.10,15,16 The re-
ported rate of hemolysis varies between 0% and 3.5%.6is view showing no residual flow across the duct (b)
sternal long axis view showing unobstructed flow in
monary artery.
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before, during, and after deployment of the device. The rea-
sons for using arterial access is that it allows initial aortog-
raphy to be performed without crossing the duct, supposedly
minimizing the risk of ductal spasm and consequent under-
estimation of the size of the duct. Also, it permits subsequent
aortography to confirm a good position of the device prior to
release and to exclude iatrogenic coarctation. It is our expe-
rience, and that of others,17 that ductal spasm may occur
whether the duct is crossed or not. Arterial access in children
is reported to have a high rate of complication ranging be-
tween 3.7 and 16%, with a significant proportion of compli-
cations requiring intervention.3,18 Complications such as
arterial disruption, or acute occlusion, may be limb- threat-
ening.19 Although the use of thrombolytics has been found to
be effective in treating femoral arterial thrombosis,19 a pro-
portion of children still have absent or diminished pulses in
the foot at the time of discharge, and the drugs themselves are
not risk-free. Chronic occlusion of the ilio-femoral arteries
after catheterization can result in claudication, inequality in
the length of the legs, and disturbance of gait that is particu-
larly important in children with growing epiphyses.20 Surgery
may be required later to treat such disturbances.
This study demonstrates the feasibility of closure of the
PDA using venous access alone. In a consecutive series of 179
patients evaluated at our institute, we were able to close PDAs
in 151 patients with venous access alone. The key steps in our
opinion, included, careful patient selection by thorough 2D
and color flow imaging, angiographic definition of the duct
and ampulla by hand injection within the duct ampulla or
proximal descending thoracic aorta and, the use of color flow
imaging to assess residual flows.
The advantages of avoiding arterial access include, avoid-
ing heparinization thereby potentially accelerating flow
elimination across the duct and elimination of inherent risks
of arterial puncture (bleeding, femoral artery thrombosis). The
procedure is considerably short as indicated by the short
fluoroscopy time21 and many patients can potentially be dis-
charged early.
The potential limitations of this approach are as follows:
1. A good echocardiographic window is a requirement. A poor
echocardiographic windowwas relatively more common in
older children, where accurate assessment of the duct size
was challenging. In these patients, the pre procedural
visualization of the duct and its sizing was adequately
assessed by the angiographic measurement from the
venous side. Most of these patients were older children and
device position and residual flowwere reasonably assessed
even with echocardiography.
2. The need for arterial access for assessment of aortic flow in
a small child with large device was needed in three
patients.
3. An echocardiography machine needs to be available in the
cardiac catheterization laboratory. This may not always be
possible in all institutions.
4. Device embolization: In the event of device embolization,
arterial access is necessary to monitor hemodynamics and
may be required when attempting to retrieve the device. In
case the device embolizes into the descending aorta, thepulses may be feeble and obtaining arterial access may be
an issue.5. Conclusions
PDA device closure without the use of arterial access can be
performed safely and effectively. Patient selection and pre
procedural planning by detailed echocardiography are
essential for accomplishing device closure of PDA without
arterial access. The procedure is simplified considerably and
many patients can be discharged on the day of the procedure.
The procedure is relatively straight forward in older children
and small to moderate sized ducts in smaller children. This
technique is also feasible in carefully selected infants with
large ducts. With increasing experience, it may be possible to
occlude the PDA of small children with large ducts without
arterial access.Conflicts of interest
All authors have none to declare.Appendix A. Supplementary data
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